| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8964536 | Journal of American Association for Pediatric Ophthalmology and Strabismus | 2018 | 11 Pages |
Abstract
We present the first reported case of Graves' orbitopathy induced by pembrolizumab, a new FDA-approved drug used for the treatment of multiple refractory solid tumors and classic Hodgkin lymphoma. Pembrolizumab elicits T-lymphocyte proliferation; we suspect that thyroid eye disease may result in some cases.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Ella S.Y. MS, Guilherme MD, Ole-Petter R. MD, Linda R. MD,